



HHS Public Access

Author manuscript

Nat Genet. Author manuscript; available in PMC 2016 July 03.

Published in final edited form as:

Nat Genet. 2015 August ; 47(8): 898–905. doi:10.1038/ng.3353.

Additive and interaction effects at three amino acid positions in HLA-DQ and HLA-DR molecules drive type 1 diabetes risk

Xinli Hu^{1,2,3,4,5,6,15}, Aaron J Deutsch^{1,2,3,4,5,15}, Tobias L Lenz^{2,7}, Suna Onengut-Gumuscu⁸, Buhm Han^{2,4,9}, Wei-Min Chen⁸, Joanna M M Howson¹⁰, John A Todd¹¹, Paul I W de Bakker^{12,13}, Stephen S Rich⁸, and Soumya Raychaudhuri^{1,2,3,4,14}

¹Department of Medicine, Brigham and Women's Hospital, Division of Rheumatology, Immunology and Allergy, Boston, Massachusetts, USA ²Department of Medicine, Brigham and Women's Hospital, Division of Genetics, Harvard Medical School, Boston, Massachusetts, USA ³Partners Center for Personalized Genetic Medicine, Boston, Massachusetts, USA ⁴Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA ⁵Harvard-MIT Division of Health Sciences and Technology, Boston, Massachusetts, USA ⁶Division of Medical Sciences, Harvard Medical School, Boston, Massachusetts, USA ⁷Evolutionary Immunogenomics, Department of Evolutionary Ecology, Max Planck Institute for Evolutionary Biology, Plön, Germany ⁸Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia, USA ⁹Asan Institute for Life Sciences, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea ¹⁰Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK ¹¹Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK ¹²Department of Medical Genetics, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands ¹³Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands ¹⁴Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK

Abstract

Variation in the human leukocyte antigen (HLA) genes accounts for one-half of the genetic risk in type 1 diabetes (T1D). Amino acid changes in the HLA-DR and HLA-DQ molecules mediate most of the risk, but extensive linkage disequilibrium complicates the localization of independent

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>.

Correspondence should be addressed to S.R. (soumya@broadinstitute.org).

¹⁵These authors contributed equally to this work.

AUTHOR CONTRIBUTIONS

X.H. and S.R. conceived the study. X.H., A.J.D., T.L.L., S.R., B.H., P.I.W.d.B. and S.S.R. contributed to the study design and analysis strategy. X.H., A.J.D., T.L.L. and S.R. conducted all analyses. X.H. and A.J.D. wrote the initial manuscript. B.H. contributed critical analytical methods. S.O.-G., W.-M.C. and S.S.R. organized and contributed subject samples and provided SNP genotype data. J.M.M.H., J.A.T., P.I.W.d.B., S.S.R. and S.R. contributed critical writing and review of the manuscript. All authors contributed to the final manuscript.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

effects. Using 18,832 case-control samples, we localized the signal to 3 amino acid positions in HLA-DQ and HLA-DR. HLA-DQ β 1 position 57 (previously known; $P = 1 \times 10^{-1,355}$) by itself explained 15.2% of the total phenotypic variance. Independent effects at HLA-DR β 1 positions 13 ($P = 1 \times 10^{-721}$) and 71 ($P = 1 \times 10^{-95}$) increased the proportion of variance explained to 26.9%. The three positions together explained 90% of the phenotypic variance in the *HLA-DRB1–HLA-DQA1–HLA-DQB1* locus. Additionally, we observed significant interactions for 11 of 21 pairs of common *HLA-DRB1–HLA-DQA1–HLA-DQB1* haplotypes ($P = 1.6 \times 10^{-64}$). HLA-DR β 1 positions 13 and 71 implicate the P4 pocket in the antigen-binding groove, thus pointing to another critical protein structure for T1D risk, in addition to the HLA-DQ P9 pocket.

T1D is a highly heritable autoimmune disease that results from T cell-mediated destruction of insulin-producing pancreatic β cells. The worldwide incidence of T1D ranges from 0.1 per 100,000 persons in China to >36 per 100,000 persons in parts of Europe and has been steadily increasing¹. Many autoimmune diseases, including T1D, rheumatoid arthritis, celiac disease and multiple sclerosis, have more genetic risk attributed to variants in the HLA genes within the major histocompatibility complex (MHC) region^{2–4} located at 6p21.3 than any other locus. HLA genes encode cell surface proteins that display antigenic peptides to effector immune cells to regulate self-tolerance and downstream immune responses. The risk of autoimmunity conferred by HLA molecules is likely the result of variation in amino acid residues at specific positions within the antigen-binding grooves, which may alter the repertoire of presented peptides^{5–8}. In T1D, the largest allelic associations are in the *HLA-DRB1–HLA-DQA1–HLA-DQB1* region, a three-gene ‘superlocus’ that encodes HLA-DR and HLA-DQ proteins^{9,10}; additional associations have been identified in the genes encoding HLA-A, HLA-B, HLA-C and HLA-DP^{11–14}.

Todd *et al.*¹⁵ initially identified strong T1D risk conferred by non-aspartate residues at position 57 of HLA-DQ β 1. However, this amino acid position alone does not fully explain the HLA-mediated risk of T1D. Subsequently, many amino acid positions in HLA-DQ β 1 and HLA-DR β 1 have been hypothesized to modify risk¹⁶, but extensive linkage disequilibrium (LD) spanning the 4-Mb MHC region makes it challenging to pinpoint the specific risk-associated variants. In addition, certain heterozygous genotypes confer the greatest disease risk^{13,17–19}, consistent with synergistic interactions between classical HLA alleles. Despite evidence of non-additive effects within the MHC region on autoimmune disease risk, interactions have not been comprehensively examined in T1D. If risk-conferring amino acid positions and their interactions were understood, mechanistic investigation of how autoantigens interact with HLA proteins could become feasible. In this study, we used recently established accurate genotype imputation methods to examine a large case-control sample and rigorously identified independent amino acid positions, as well as interactions within the HLA region, that account for T1D risk (see Supplementary Fig. 1 for a schematic of the analyses).

RESULTS

HLA imputation and association testing

We fine mapped the MHC region in a collection of 8,095 T1D cases and 10,737 controls genotyped with the Immuchip array, provided by the Type 1 Diabetes Genetics Consortium (T1DGC)^{20–22}. The data set included (i) case-control samples collected in the UK and (ii) a pseudocase-control set derived from European families (Online Methods and Supplementary Table 1). Using a set of 5,225 individuals with classical HLA typing as a reference²², we accurately imputed 8,617 binary markers (with minor allele frequency > 0.05%) from ~29 Mb to ~33 Mb on chromosome 6p21.3 (the 4-Mb classical MHC region) with SNP2HLA software²¹. The resulting data included 7,242 SNPs, 260 2- and 4-digit classical alleles, and amino acid residues at 399 positions for 8 HLA genes (*HLA-A*, *HLA-B*, *HLA-C*, *HLA-DRB1*, *HLA-DQA1*, *HLA-DQB1*, *HLA-DPA1* and *HLA-DPB1*) with high imputation quality (INFO score >0.96; see Supplementary Table 2 for the list of variants and imputation quality). We have previously independently benchmarked the imputation strategy employed in this study for accuracy using a set of 918 samples with gold-standard HLA typing data. Starting with SNPs from the Immuchip genotyping platform and using the T1DGC reference panel, SNP2HLA obtained accuracies of 98.4%, 96.7% and 99.3% for all 2-digit alleles, 4-digit alleles and amino acid polymorphisms, respectively²¹.

To test for T1D association with a given variant, we used a logistic regression model, assuming the log odds of disease to be proportional to the allelic dosage of the variant. We also included covariates to adjust for sex and region of origin (Supplementary Fig. 2 and Supplementary Note). As expected, the strongest associations with T1D were within the *HLA-DRB1–HLA-DQA1–HLA-DQB1* locus. We confirmed that the leading risk variant was the presence of alanine at HLA-DQB1 position 57 ($P = 1 \times 10^{-1,090}$; odds ratio (OR) = 5.17; Fig. 1a and Supplementary Table 2). In contrast, the single most significantly associated classical allele was HLA-DQB1*03:02 ($P = 1 \times 10^{-840}$), which encodes an alanine at HLA-DQB1 position 57, although the classical allele was much more weakly associated than the amino acid residue itself. Common classical alleles tagged by each residue at key amino acid positions are listed in Table 1.

Three amino acid positions independently drive T1D risk

Given the strength and complexity of the association within *HLA-DRB1–HLA-DQA1–HLA-DQB1*, we aimed to first identify independent effects in this locus before examining the rest of the MHC region. We assessed the significance of multiallelic amino acid positions using conditional analysis by forward search (Online Methods). Unsurprisingly, the position most strongly associated with T1D was HLA-DQB1 residue 57 (omnibus $P = 1 \times 10^{-1,355}$; Fig. 2 and Supplementary Tables 3 and 4a). At this position, alanine conferred the strongest risk (OR = 5.17; Fig. 3), whereas the most common residue in controls, aspartic acid, was the most protective (OR = 0.16). Conditioning on HLA-DQB1 position 57, the second independent association was at HLA-DRB1 position 13 (omnibus $P = 1 \times 10^{-721}$; Fig. 2). At this position, histidine (OR = 3.64) and serine (OR = 1.28) conferred the strongest risk, whereas arginine (OR = 0.08) and tyrosine (OR = 0.28) were protective (Fig. 3 and Supplementary Table 4a). The HLA-DRB1 residue at position 71 was the third

independently associated signal (omnibus $P = 1 \times 10^{-95}$; Fig. 2); lysine conferred strong risk (OR = 4.70), and alanine was strongly protective (OR = 0.04; Fig. 3 and Supplementary Table 4a). We note that, at these positions, the risk-conferring amino acid residues indeed tagged the HLA-DR3 and HLA-DR4 haplotypes, which confer the strongest risk among haplotypes. Histidine at position 13 tagged HLA-DRB1*04:01 and HLA-DRB1*04:04, whereas serine at this position tagged HLA-DRB1*03:01. Lysine at position 71 tagged both HLA-DRB1*03:01 and HLA-DRB1*04:01. The classical alleles tagged by residues at each key amino acid position and multivariate OR estimates for the haplotypes defined by these positions are listed in Table 1 and Supplementary Table 6.

Given the reported deviation from log-scale additivity for T1D risk effects in the HLA region^{19,23}, we wanted to confirm that the contribution of these effects did not alter the risk-driving amino acid positions. By repeating the forward-search analysis while including non-additive terms in the regression model, we confirmed that HLA-DQB1 position 57, HLA-DRβ1 position 13 and HLA-DRβ1 position 71 were the top three independent signals under the non-additive model as well as the additive model (Supplementary Fig. 3 and Supplementary Note).

We exhaustively tested all possible combinations of two, three and four amino acid positions for *HLA-DRB1*–*HLA-DQA1*–*HLA-DQB1* and confirmed that HLA-DQB1 position 57, HLA-DRβ1 position 13 and HLA-DRβ1 position 71 were the most strongly associated of all 457,450 combinations of 3 amino acids ($P = 1 \times 10^{-2,161}$; Supplementary Table 7). When conditioning on these 3 positions, more than 80 other positions and classical alleles remained highly significant ($P < 1 \times 10^{-8}$; Supplementary Table 4b,c), suggesting the presence of other independent associations. HLA-DQB1 position –18 (located within the signal peptide) emerged as the fourth most significant association ($P = 1 \times 10^{-40}$) through the forward search; however, in the exhaustive test, many other combinations of four amino acid positions exceeded the goodness-of-fit for HLA-DQB1 position 57, HLA-DRβ1 position 13, HLA-DRβ1 position 71 and HLA-DQB1 position –18 (Supplementary Table 7). Therefore, we do not report subsequent positions that emerged through conditional analysis, as we could not confidently claim additional positions as independent drivers of T1D risk.

We wanted to confirm that the top three amino acid positions were not simply tagging the effects of specific haplotypes. To this end, we performed a permutation analysis in which we randomly reassigned amino acid sequences corresponding to each *HLA-DRB1*, *HLA-DQB1* and *HLA-DQA1* classical allele and retested for the most strongly associated amino acid positions (Online Methods). This approach preserved haplotypic associations; thus, if certain amino acids were tagging associated haplotypes, equally significant amino acid associations would be found in the permuted data. After 10,000 permutations, no combination of permuted amino acids resulted in a model that equaled or exceeded the goodness-of-fit for HLA-DQB1 position 57, HLA-DRβ1 position 13 and HLA-DRβ1 position 71 in our data, as measured by either deviance or P value (Supplementary Fig. 4).

Finally, to ensure that the observed effects were not the result of heterogeneity between the UK and European subsets, we repeated the association analysis separately in the two subsets. The two sets yielded highly correlated effect sizes for all binary markers (Pearson r

= 0.952; Supplementary Fig. 5a), as well as for all haplotypes formed by residues at HLA-DQ β 1 position 57, HLA-DR β 1 position 13 and HLA-DR β 1 position 71 (Pearson r = 0.989; Supplementary Fig. 5b).

Key amino acids are located in the peptide-binding grooves

HLA-DQ β 1 position 57, HLA-DR β 1 position 13 and HLA-DR β 1 position 71 are each located in the peptide-binding groove of the respective HLA molecule (Fig. 4). HLA-DR β 1 positions 13 and 71 line the P4 pocket of HLA-DR, which has previously been implicated in seropositive² and seronegative²⁴ rheumatoid arthritis and follicular lymphoma²⁵. Although HLA-DR β 1 positions 13 and 71 are both involved in T1D and rheumatoid arthritis, the effects of individual residues at each position were discordant between the diseases ($P < 1 \times 10^{-232}$; Online Methods and Supplementary Fig. 6).

Variance explained by the three amino acid positions in *HLA-DRB1–HLA-DQA1–HLA-DQB1*

We quantified the proportion of phenotypic variance captured by the three amino acid positions using the liability threshold model²⁶ (Supplementary Note). Assuming a T1D prevalence of 0.4% (ref. 27), the additive effects of all 67 haplotypes for *HLA-DRB1–HLA-DQA1–HLA-DQB1* explained 29.6% of the total phenotypic variance (Supplementary Table 6). HLA-DQ β 1 position 57 alone explained 15.2% of the total variance, and the addition of HLA-DR β 1 position 13 and HLA-DR β 1 position 71 increased the proportion explained by 11.7%. Therefore, these three amino acid positions together capture 26.9% of the total variance, accounting for over 90% of the T1D-HLA association in this locus (Fig. 5).

Independent HLA associations in *HLA-B*, *HLA-DPB1* and *HLA-A*

We then sought to identify HLA associations with T1D independent of those in the *HLA-DRB1–HLA-DQA1–HLA-DQB1* locus. We conservatively conditioned on all *HLA-DRB1*, *HLA-DQA1* and *HLA-DQB1* four-digit classical alleles to eliminate all effects at these loci. We observed the next strongest association across the MHC region in *HLA-B*, where the classical allele HLA-B*39:06 was the most significant signal (OR = 6.64; $P = 1 \times 10^{-75}$; Fig. 1b and Supplementary Table 5a)¹¹. After adjusting for HLA-B*39:06, other classical alleles and amino acid positions in *HLA-B* remained significantly associated, including HLA-B*18:01 and HLA-B*50:01. Upon additionally adjusting for all *HLA-B* alleles, HLA-DPB1*04:02 was the next strongest independent signal (OR = 0.47; $P < 1 \times 10^{-55}$; Fig. 1c), which is nearly perfectly tagged by methionine at amino acid position 178 of HLA-DP β 1. Conditioning on HLA-DPB1*04:02, additional associations were present for *HLA-DPB1*, including amino acid position 65 and HLA-DPB1*01:01 (Supplementary Table 5b). After conditioning on *HLA-DPB1* alleles as well, we observed independent effects in *HLA-A* led by amino acid position 62 ($P = 1 \times 10^{-45}$; Fig. 1d); additional signals included HLA-A*03 and HLA-A*24:02 (Supplementary Table 5c). We observed no independent association with T1D in *HLA-C* or *HLA-DPA1* (Fig. 1e). The independent effects of all haplotypes in *HLA-B*, *HLA-DPB1* and *HLA-A* together explained ~4% of the total phenotypic variance. The total T1D risk variance explained by additive effects in the eight HLA genes was ~34%, consistent with the estimates by Speed *et al.*²⁸.

HLA haplotypic interaction effects are common in T1D

The previously observed excess risk of T1D in HLA-DR3/HLA-DR4 heterozygotes (HLA-DRB1*03:01–HLA-DQA1*05:01–HLA-DQB1*02:01/HLA-DRB1*04:XX–HLA-DQA1*03:01–HLA-DQB1*03:02) might represent a synergistic interaction between two distinct alleles²³. Here we conducted an unbiased search for interactions among all haplotypes within the *HLA-DRB1–HLA-DQA1–HLA-DQB1* locus (Online Methods). As interactions cannot be observed reliably with rare genotypes, we focused this analysis on the seven *HLA-DRB1–HLA-DQA1–HLA-DQB1* haplotypes with frequencies >5%; all of these haplotypes had very high imputation accuracies (INFO score > 0.94; Supplementary Table 8 and Supplementary Note).

We tested for interactions between all possible pairs of haplotypes using a global multivariate regression model that included 21 interaction terms as well as 7 additive terms. The inclusion of interactions in the model resulted in a statistically significant improvement in fit over the additive model ($P = 1.6 \times 10^{-64}$). Of the 21 potential interactions, 11 were significant after correcting for the 21 tests ($P < 0.05/21 = 2.4 \times 10^{-3}$; Fig. 6, Table 2 and Supplementary Table 9). Consistent with previous reports^{9,19}, we observed a significant interaction between the HLA-DR3 haplotype (HLA-DRB1*03:01–HLA-DQA1*05:01–HLA-DQB1*02:01) and the HLA-DR4 haplotype (HLA-DRB1*04:01–HLA-DQA1*03:01–HLA-DQB1*03:02) ($P = 1.2 \times 10^{-5}$). This interaction resulted in an OR of 30.42, in comparison to an expected OR of 15.51 due to only additive contributions. Likewise, we confirmed an independent interaction between HLA-DRB1*03:01–HLA-DQA1*05:01–HLA-DQB1*02:01 and HLA-DRB1*04:04–HLA-DQA1*03:01–HLA-DQB1*03:02 ($P = 1.9 \times 10^{-4}$).

We observed many other significant haplotypic interactions beyond the well-studied HLA-DR3/HLA-DR4 heterozygote effect (Table 2 and Supplementary Table 9). Most interactions increased T1D risk. For example, the combination of HLA-DRB1*04:01–HLA-DQA1*03:01–HLA-DQB1*03:02 and HLA-DRB1*07:01–HLA-DQA1*02:01–HLA-DQB1*02:02 dramatically increased risk by 5.09-fold (beyond the risk predicted by the additive model). Other pairs significantly reduced risk. Notably, whereas HLA-DRB1*04:01–HLA-DQA1*03:01–HLA-DQB1*03:02 and HLA-DRB1*04:04–HLA-DQA1*03:01–HLA-DQB1*03:02 each conferred risk, the heterozygous combination elicited a threefold reduction relative to the expected risk. Because we restricted our analysis to haplotypes with an allele frequency of at least 5%, other interaction effects are likely present but unobserved¹⁹.

Interaction effects are mediated by HLA-DQβ1 57 and HLA-DRβ1 13

The HLA-DQ αβ *trans* heterodimer formed by the proteins encoded by HLA-DQA1*05:01 and HLA-DQB1*03:02 may confer a particularly high risk for individuals with the HLA-DR3/HLA-DR4 genotype owing to its unique antigen-binding properties²⁹. To identify the possible drivers of this haplotypic interaction, we tested pairwise interactions among the *HLA-DRB1*, *HLA-DQA1* and *HLA-DQB1* four-digit alleles. We observed a significant interaction between HLA-DQA1*05:01 and HLA-DQB1*03:02 ($P = 1.71 \times 10^{-25}$). However, because of high LD across the locus, several pairs of classical alleles (including

HLA-DQB1*02:01/HLA-DQB1*03:02 and HLA-DRB1*03:01/HLA-DQB1*03:02; Supplementary Table 10) achieved similarly significant *P* values. Therefore, although our model is consistent with a risk-conferring interaction between HLA-DQA1*05:01 and HLA-DQB1*03:02, we cannot eliminate the possibility that interactions between other alleles within the two haplotypes are driving this specific interaction.

We next assessed whether these haplotypic interactions could be explained by amino acid positions. We exhaustively tested for all pairwise interactions among amino acid residues for *HLA-DRB1–HLA-DQA1–HLA-DQB1*, again limiting the analysis to residues with a frequency of at least 5%. Of the 3,773 pairs of amino acid positions tested, we observed that interactions between HLA-DQβ1 position 57 and HLA-DRβ1 position 13 yielded the largest improvement over the additive model (Supplementary Table 11). We note that two other pairs of amino acid positions achieved similarly significant *P* values. These analyses suggest that the same amino acid positions that explain the greatest proportion of the additive risk may also be the positions that mediate interaction effects within this locus.

DISCUSSION

Fine mapping the MHC locus in T1D demonstrates that amino acid polymorphisms at HLA-DQβ1 position 57, HLA-DRβ1 position 13 and HLA-DRβ1 position 71 independently modulate T1D risk and capture over 90% of the phenotypic variance explained by the *HLA-DRB1–HLA-DQA1–HLA-DQB1* locus (and 80% of the variance explained by the entire MHC region). Previous studies have suggested that other amino acid positions within the HLA class II molecules confer T1D risk (for example, HLA-DRβ1 position 86, HLA-DRβ1 position 74 and HLA-DRβ1 position 57 in the P1, P4 and P9 pockets, respectively)¹⁶. Although our analysis highlights the top three amino acid positions as the main contributors of T1D risk, there is also evidence of other allelic effects within the *HLA-DRB1–HLA-DQA1–HLA-DQB1* locus; however, the corresponding relative effect sizes were very modest in comparison to those for the three leading positions identified. We note that our results are derived from cases and controls from a relatively homogeneous population (from the UK), and our ability to interrogate rare alleles in this population may be limited. For instance, HLA-DRB1*04:03, a common protective allele in the Sardinian population highlighted by Cucca *et al.*¹⁶, is rare in this data set, with an allele frequency of 0.3%. As such, the observed effects of amino acid positions that best define this allele (HLA-DRβ1 positions 74 and 86) may have been less pronounced than what might be observed in a more diverse data set. Additional variants may be conclusively identified in the future with increased sample size. Finally, although coding variants contribute to the majority of the phenotypic variance in T1D, there is the possibility that there are other mechanisms, such as gene and protein expression, that further modulate susceptibility^{30,31}.

Beyond the previously described HLA-DR3/HLA-DR4 interactions, we find nine additional pairwise interactions between HLA haplotypes that contribute to T1D risk, suggesting that non-additive effects are common within this locus. Notably, we showed that HLA-DQβ1 position 57 and HLA-DRβ1 position 13 are the strongest contributors to both additive and interactive risk effects. Interestingly, the two strongest interacting amino acid positions are in separate HLA molecules (HLA-DQ and HLA-DR, respectively). *HLA-DQA1*, which is in

strong LD with *HLA-DRB1* and *HLA-DQB1*, appears to have a minimal role in modulating T1D risk. This finding suggests that the interaction effects are possibly due to alteration of the antigen presentation repertoire created by the combination of different HLA molecules, rather than the consequence of specific HLA-DQ $\alpha\beta$ heterodimers with particular structural features that confer extreme binding affinities.

The HLA amino acid variants identified in our study may mediate recognition of one or more autoantigens and cause autoimmunity through different mechanisms. In particular, our findings implicate the HLA-DR P4 pocket in T1D in addition to the known role of the HLA-DQ P9 pocket; this is the first instance, to our knowledge, where the HLA-DR P4 pocket has an important but secondary role to a different locus (HLA-DQ β 1 position 57). The HLA-DR P4 pocket has been shown to have primary roles in other autoimmune diseases. For example, in rheumatoid arthritis, the risk-conferring amino acid residues in P4 likely facilitate the binding of citrullinated peptides⁷. In T1D, the anti-islet autoantibody reactivity in sera from patients is largely accounted for by four autoantigens (preproinsulin, glutamate decarboxylase (GAD), islet antigen 2 (IA-2) and ZnT8), although the identification of specific peptides that affect autoreactivity is still work in progress^{8,32–37}. Cucca *et al.* implicated the signal peptide sequences of preproinsulin as potentially important in T1D, by modeling the associations of HLA class II alleles and their polymorphic amino acid positions with structural features of the peptide-binding pockets¹⁶. The discovery of critical variants that drive T1D risk enables future functional investigations. Synthesis of HLA molecules containing single-residue alterations at risk-modulating positions may demonstrate the effects of these positions on the physicochemical properties of the antigen-binding pockets. Furthermore, the use of peptide display or small molecule libraries may directly identify and characterize peptides that differentially bind to HLA molecules that differ at risk-modulating positions, thereby uncovering the essential pathogenic peptides and the mechanisms through which they evoke autoimmunity.

ONLINE METHODS

Sample collection

The data set was provided by T1DGC²⁰ and consisted of (i) a UK case-control data set and (ii) a European family-based data set. All samples were collected after obtaining informed consent. The UK case-control data set consisted of a total of 16,086 samples (6,670 cases and 9,416 controls) from 3 collections: (i) cases from the UK-GRID, (ii) shared controls from the British 1958 Birth Cohort and (iii) shared controls from Blood Services controls (data release 4 February 2012; hg18). The UK samples were collected from 13 regions (listed in Supplementary Table 1). The European family-based data set consisted of 10,791 samples (5,571 affected children and 5,220 controls) from 2,699 European-ancestry families (data release 30 January 2013; hg18). All samples were genotyped on the ImmunoChip array. After quality control, 6,223 and 6,608 markers, respectively, were genotyped in the MHC region between 29 Mb and 45 Mb on chromosome 6 in the 2 data sets. Using the family data, we constructed 1,662 pairs of pseudocase and pseudocontrol samples (Supplementary Note).

HLA imputation

We used SNP2HLA (with default input parameters) to impute SNPs, amino acid residues, indels, and two- and four-digit classical alleles for eight HLA genes in the MHC region from 29,602,876 to 33,268,403 bp on chromosome 6. We used the reference panel provided by T1DGC, which included 5,225 European samples with classical typing for *HLA-A*, *HLA-B*, *HLA-C*, *HLA-DRB1*, *HLA-DQA1*, *HLA-DQB1*, *HLA-DPB1* and *HLA-DPA1* 4-digit alleles^{21,22}. The imputed genotype data set included 8,961 binary markers before frequency thresholding. For each marker and each individual, two types of output were produced: a phased best-guess genotype (for example, AA/AT/TT) and a dosage, which accounted for imputation uncertainty and could be continuous between 0 (0 copies of the alternative allele) and 2 (2 copies of the alternative allele).

We imputed the UK case-control data set and the European family data set independently; within each set, cases and controls were imputed together to avoid disparity in imputation quality. We used 4,604 and 5,125 SNPs in the MHC region for imputation in the UK and European data sets, respectively. After combining the UK and European data sets, we excluded a total of 344 binary markers because of allele missingness or rareness (allele frequency < 0.05%); we then removed individuals who carried the missing or rare alleles. The final data set after quality control consisted of 18,832 samples, comprising 8,095 cases (including 1,662 pseudocases) and 10,737 controls (including 1,662 pseudocontrols).

Statistical framework

We tested a given variant's association with disease status using the logistic regression model:

$$\log(\text{odds}_i) = \beta_0 + \sum_{j=1}^{m-1} \beta_{1,j} x_{i,j} + \sum_{k=1}^{n-1} \beta_{2,k} y_{i,k} + \beta_3 z_i$$

where variant x_j may be an imputed dosage or the best-guess genotype for a SNP, classical allele, amino acid or haplotype. β_0 is the logistic regression intercept and $\beta_{1,j}$ is the additive effects of allele j of variant x_j . The number of alleles at each variant is m ; for a binary variant (presence or absence of x_j), m equals 2. The covariate $y_{i,k}$ denotes each region of sample collection ($n = 14$). We included sex as covariate z . β_2 and β_3 are the effect sizes of the region and sex covariates, respectively.

To account for population stratification, we included region codes as covariates (Supplementary Note). Samples from the European data set were considered as the fourteenth region. To assess the statistical significance of a tested variant, we calculated the improvement of fit for the model containing the test variant over the null model (with only region and sex as covariates). We calculated the model improvement as deviance, defined by $\text{deviance}_{\text{alt} - \text{null}} = -2\ln(\text{likelihood}_{\text{alt}}/\text{likelihood}_{\text{null}})$, which follows a χ^2 distribution with $m - 1$ degrees of freedom, from which we calculated the P value. We considered $P = 5 \times 10^{-8}$ to be the significance threshold.

Analysis of amino acid positions

To test amino acid effects within *HLA-DRB1–HLA-DQA1–HLA-DQB1*, we applied conditional haplotypic analysis. We tested each single amino acid position by first identifying the m amino acid residues occurring at that position and partitioning all samples into m groups with identical residues at that position. We estimated the effect of each of the m groups using the logistic regression model (including covariates as above) and assessed the significance of model improvement by χ^2 deviance in comparison to the null model, with $m - 1$ degrees of freedom. This approach is equivalent to testing a single multiallelic locus for association with m alleles. To test the effect of a second amino acid position while conditioning on the first, we further updated the model to include all unique haplotypes created by residues at both positions. We then tested whether the updated model improved on the previous model by calculating χ^2 deviance, taking into consideration the increased number of degrees of freedom.

Exhaustive test

To ensure that the independently associated amino acids were not identified only as a result of the forward-search approach, which might possibly converge on local minima, we exhaustively tested all possible combinations of one, two, three and four amino acid positions for *HLA-DRB1*, *HLA-DQA1* and *HLA-DQB1*. For each number of amino acid positions being combined, we selected the best model according to χ^2 deviance from the null (with only sex and region as covariates).

Haplotype–amino acid permutation analysis

Given the polymorphic nature of the HLA genes and the strong effect sizes in the *HLA-DRB1–HLA-DQA1–HLA-DQB1* locus, we wanted to assess whether the observed associations at HLA-DQ β 1 position 57, HLA-DQ β 1 position 13 and HLA-DQ β 1 position 71 could emerge by chance, owing to the ability of these positions to tag classical alleles with different effects on risk. To eliminate this possibility, we conducted a permutation test. In each permutation, for each of the three genes (for example, *HLA-DQB1*, *HLA-DRB1* and *HLA-DQA1*), we preserved the sample's case or control status and the sex and region covariates. To maintain allelic associations, we preserved groups of samples with the same amino acid sequence (four-digit classical allele) for each gene. We then randomly reassigned the amino acid sequence corresponding to each classical allele in each permutation and repeated the forward-search analysis. We repeated this permutation 10,000 times, each time selecting the combinations of two, three and four amino acid positions that produced the best model (as measured by deviance). If the amino acids were merely tagging the effects of certain haplotypes, the effects we observed in the real data would not be more significant than those generated from permutations. To obtain the permutation-based P value, we calculated the proportion of permuted models that exceeded the goodness-of-fit of the best model in the unpermuted data.

Testing for non-additivity and interactions

We defined haplotypes across the *HLA-DRB1–HLA-DQA1–HLA-DQB1* locus on the basis of unique combinations of amino acid residues encoded across the three genes. As non-

additive effects can be observed only when sufficient numbers of homozygous individuals are present, we limited the interaction analysis to a subset of common haplotypes or classical alleles with frequencies greater than 5%. We excluded all individuals with one or more haplotypes that fell below this threshold.

We constructed an interaction model, which included additive terms for each common haplotype and interaction terms for all possible pairs of common haplotypes:

$$\log(\text{odds}_i) = \beta_0 + \sum_{j=1}^{m-1} \beta_{i,j} x_{i,j} + \sum_{j=1}^{m-1} \sum_{l=j+1}^m \varphi_{j,l} x_{i,j} x_{j,l} + \sum_{k=1}^{n-1} \beta_{2,k} y_{i,k} + \beta_3 z_i$$

where φ is the interaction effect size. We determined the improvement in fit with each successive model by calculating the change in deviance and used a significance threshold of $P = 0.05/h$, where h is the total number of interaction parameters added to the original additive model.

HLA-DR3/HLA-DR4 classical allele interactions

To characterize the HLA-DR3/HLA-DR4 interaction, we defined 12 interaction terms, where each term represented a potential interaction between a classical allele on the HLA-DR3 haplotype (HLA-DRB1*03:01, HLA-DQA1*05:01 and HLA-DQB1*02:01) and a classical allele on the HLA-DR4 haplotype (HLA-DRB1*04:01 or HLA-DRB1*04:04, HLA-DQA1*03:01 and HLA-DQB1*03:02). We only looked at *trans* interactions, as haplotype analyses already account for classical alleles that occur together in *cis*. We began with a null model that included additive effects for all haplotypes. We then tested each of the 12 interaction terms individually by adding each term to the null model separately. Once again, we used the change in deviance to assess the improvement in fit, using $P = 0.05/21 = 2.4 \times 10^{-3}$ as the threshold for significance.

Amino acid interaction analysis

To determine whether amino acid positions could explain haplotypic interactions, we defined haplotypes across the *HLA-DRB1–HLA-DQA1–HLA-DQB1* locus on the basis of the 141 amino acid positions imputed for this locus. To ensure that a sufficiently large number of homozygous individuals were present, we excluded all amino acid residues with a frequency less than 5% before creating the haplotypes. We also excluded any individual who had one or more amino acids that fell below this threshold.

We began with a null model that included additive effects for each amino acid haplotype. Then, for each pair of amino acid positions $\{q, r\}$, we added a set of $n_q \times n_r$ interaction terms, where each term specifies a *trans* interaction between one variant at each position and n_p represents the total number of variants at position p . Each pair of amino acids was tested in a separate model, and we calculated the change in deviance to determine the improvement in fit. Monomorphic amino acid positions were excluded from this analysis, as they were constant across all individuals.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research makes use of resources provided by the Type 1 Diabetes Genetics Consortium (T1DGC), a collaborative clinical study sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute of Allergy and Infectious Diseases (NIAID), the National Human Genome Research Institute (NHGRI), the National Institute of Child Health and Human Development (NICHD) and Juvenile Diabetes Research Foundation International (JDRFI) and supported by grant U01DK062418. This work is supported in part by funding from the US National Institutes of Health (5R01AR062886-02 (P.I.W.d.B.), 1R01AR063759 (S.R.), 5U01GM092691-05 (S.R.), 1UH2AR067677-01 (S.R.) and R01AR065183 (P.I.W.d.B.)), a Doris Duke Clinical Scientist Development Award (S.R.), the Wellcome Trust (J.A.T.) and the UK National Institute for Health Research (NIHR; J.A.T. and J.M.M.H.) and by a Vernieuwingsimpuls VIDI Award (016.126.354) from the Netherlands Organization for Scientific Research (P.I.W.d.B.). T.L.L. was supported by the German Research Foundation (LE 2593/1-1 and LE 2593/2-1).

References

1. Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. *Endocrinol Metab Clin North Am.* 2010; 39:481–497. [PubMed: 20723815]
2. Raychaudhuri S, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. *Nat Genet.* 2012; 44:291–296. [PubMed: 22286218]
3. Trynka G, Wijmenga C, van Heel DA. A genetic perspective on coeliac disease. *Trends Mol Med.* 2010; 16:537–550. [PubMed: 20947431]
4. Gourraud PA, Harbo HF, Hauser SL, Baranzini SE. The genetics of multiple sclerosis: an up-to-date review. *Immunol Rev.* 2012; 248:87–103. [PubMed: 22725956]
5. Lee KH, Wucherpennig KW, Wiley DC. Structure of a human insulin peptide–HLA-DQ8 complex and susceptibility to type 1 diabetes. *Nat Immunol.* 2001; 2:501–507. [PubMed: 11376336]
6. Astill TP, Ellis RJ, Arif S, Tree TI, Peakman M. Promiscuous binding of proinsulin peptides to Type 1 diabetes–permissive and –protective HLA class II molecules. *Diabetologia.* 2003; 46:496–503. [PubMed: 12684749]
7. Scally SW, et al. A molecular basis for the association of the *HLA-DRB1* locus, citrullination, and rheumatoid arthritis. *J Exp Med.* 2013; 210:2569–2582. [PubMed: 24190431]
8. van Lummel M, et al. Posttranslational modification of HLA-DQ binding islet autoantigens in type 1 diabetes. *Diabetes.* 2014; 63:237–247. [PubMed: 24089515]
9. Erlich H, et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the Type 1 Diabetes Genetics Consortium families. *Diabetes.* 2008; 57:1084–1092. [PubMed: 18252895]
10. Noble JA, et al. The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. *Am J Hum Genet.* 1996; 59:1134–1148. [PubMed: 8900244]
11. Nejentsev S, et al. Localization of type 1 diabetes susceptibility to the MHC class I genes *HLA-B* and *HLA-A*. *Nature.* 2007; 450:887–892. [PubMed: 18004301]
12. Cucca F, et al. The *HLA-DPB1*-associated component of the IDDM1 and its relationship to the major loci *HLA-DQB1*, *-DQA1*, and *-DRB1*. *Diabetes.* 2001; 50:1200–1205. [PubMed: 11334427]
13. Deschamps I, et al. HLA genotype studies in juvenile insulin-dependent diabetes. *Diabetologia.* 1980; 19:189–193. [PubMed: 7409364]
14. Howson JM, Walker NM, Clayton D, Todd JA. Type 1 Diabetes Genetics Consortium. Confirmation of HLA class II independent type 1 diabetes associations in the major histocompatibility complex including *HLA-B* and *HLA-A*. *Diabetes Obes Metab.* 2009; 11(suppl 1):31–45. [PubMed: 19143813]

15. Todd JA, Bell JI, McDevitt HO. HLA-DQ β gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. *Nature*. 1987; 329:599–604. [PubMed: 3309680]
16. Cucca F, et al. A correlation between the relative predisposition of MHC class II alleles to type 1 diabetes and the structure of their proteins. *Hum Mol Genet*. 2001; 10:2025–2037. [PubMed: 11590120]
17. Thomson G, et al. Genetic heterogeneity, modes of inheritance, and risk estimates for a joint study of Caucasians with insulin-dependent diabetes mellitus. *Am J Hum Genet*. 1988; 43:799–816. [PubMed: 3057885]
18. Svejgaard A, Ryder LP. HLA genotype distribution and genetic models of insulin-dependent diabetes mellitus. *Ann Hum Genet*. 1981; 45:293–298. [PubMed: 6946724]
19. Koeleman BP, et al. Genotype effects and epistasis in type 1 diabetes and HLA-DQ *trans* dimer associations with disease. *Genes Immun*. 2004; 5:381–388. [PubMed: 15164102]
20. Onengut-Gumuscu S, et al. Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. *Nat Genet*. 2015; 47:381–386. [PubMed: 25751624]
21. Jia X, et al. Imputing amino acid polymorphisms in human leukocyte antigens. *PLoS ONE*. 2013; 8:e64683. [PubMed: 23762245]
22. Brown WM, et al. Overview of the MHC fine mapping data. *Diabetes Obes Metab*. 2009; 11(suppl 1):2–7. [PubMed: 19143809]
23. Noble JA, Erlich HA. Genetics of type 1 diabetes. *Cold Spring Harb Perspect Med*. 2012; 2:a007732. [PubMed: 22315720]
24. Han B, et al. Fine mapping seronegative and seropositive rheumatoid arthritis to shared and distinct HLA alleles by adjusting for the effects of heterogeneity. *Am J Hum Genet*. 2014; 94:522–532. [PubMed: 24656864]
25. Foo JN, et al. Coding variants at hexa-allelic amino acid 13 of HLA-DRB1 explain independent SNP associations with follicular lymphoma risk. *Am J Hum Genet*. 2013; 93:167–172. [PubMed: 23791106]
26. Witte JS, Visscher PM, Wray NR. The contribution of genetic variants to disease depends on the ruler. *Nat Rev Genet*. 2014; 15:765–776. [PubMed: 25223781]
27. Sivertsen B, Petrie KJ, Wilhelmsen-Langeland A, Hysing M. Mental health in adolescents with Type 1 diabetes: results from a large population-based study. *BMC Endocr Disord*. 2014; 14:83. [PubMed: 25303963]
28. Speed D, Hemani G, Johnson MR, Balding DJ. Improved heritability estimation from genome-wide SNPs. *Am J Hum Genet*. 2012; 91:1011–1021. [PubMed: 23217325]
29. Reichstetter S, Kwok WW, Nepom GT. Impaired binding of a DQ2 and DQ8-binding HSV VP16 peptide to a DQA1*0501/DQB1*0302 *trans* class II heterodimer. *Tissue Antigens*. 1999; 53:101–105. [PubMed: 10082436]
30. Ettinger RA, Liu AW, Nepom GT, Kwok WW. Exceptional stability of the HLA-DQA1*0102/DQB1*0602 $\alpha\beta$ protein dimer, the class II MHC molecule associated with protection from insulin-dependent diabetes mellitus. *J Immunol*. 1998; 161:6439–6445. [PubMed: 9834137]
31. Miyadera H, Ohashi J, Lernmark A, Kitamura T, Tokunaga K. Cell-surface MHC density profiling reveals instability of autoimmunity-associated HLA. *J Clin Invest*. 2015; 125:275–291. [PubMed: 25485681]
32. Knight RR, et al. A distinct immunogenic region of glutamic acid decarboxylase 65 is naturally processed and presented by human islet cells to cytotoxic CD8 T cells. *Clin Exp Immunol*. 2015; 179:100–107. [PubMed: 25112375]
33. Kronenberg D, et al. Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill β -cells. *Diabetes*. 2012; 61:1752–1759. [PubMed: 22522618]
34. Nakayama M, et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. *Nature*. 2005; 435:220–223. [PubMed: 15889095]
35. Baekkeskov S, et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. *Nature*. 1990; 347:151–156. [PubMed: 1697648]

36. Karlsen AE, et al. Recombinant glutamic acid decarboxylase (representing the single isoform expressed in human islets) detects IDDM-associated 64,000- M_r autoantibodies. *Diabetes*. 1992; 41:1355–1359. [PubMed: 1397711]
37. Roep BO, Peakman M. Antigen targets of type 1 diabetes autoimmunity. *Cold Spring Harb Perspect Med*. 2012; 2:a007781. [PubMed: 22474615]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 1.

HLA loci independently associated with T1D. Each binary marker was tested for T1D association, using the imputed allelic dosage (between 0 and 2). In each panel, the horizontal dashed line marks $P = 5 \times 10^{-8}$. The color gradient of the diamonds indicates LD (r^2) with the most strongly associated variant; the darkest shade represents $r^2 = 1$. (a) The strongest associations were located in the *HLA-DRB1*–*HLA-DQA1*–*HLA-DQB1* locus. The single strongest risk variant was alanine at HLA-DQ β 1 position 57 (OR = 5.17; $P = 1 \times 10^{-1,090}$). See Supplementary Table 2 for unadjusted associations for all markers. (b) Adjusting for all *HLA-DRB1*, *HLA-DQA1* and *HLA-DQB1* four-digit classical alleles, the strongest independent signals were in *HLA-B*. The strongest association was with HLA-B*39:06 (OR = 6.64; $P = 1 \times 10^{-75}$). (c) Adjusting for *HLA-DRB1*–*HLA-DQA1*–*HLA-DQB1* and *HLA-B*, the next strongly associated variant was HLA-DPB1*04:02 (OR = 0.48; $P = 1 \times 10^{-55}$). (d) The final independent association was in *HLA-A*, led by glutamine at HLA-A position 62 (OR = 0.70; $P = 1 \times 10^{-25}$). (e) We found no residual independent association in the *HLA-C* or *HLA-DPA1* genes.




Figure 2.

Amino acid residues at HLA-DQβ1 position 57, HLA-DRβ1 position 13 and HLA-DRβ1 position 71 independently drive T1D risk associated with the *HLA-DRB1–HLA-DQA1–HLA-DQB1* locus. To identify each independently associated position, we used conditional haplotypic analysis by forward search, using phased best-guess genotypes. In each panel, the dots mark amino acid positions along the gene (*x* axis) and their association *P* values (\log_{10} ; *y* axis). The horizontal dashed lines mark the \log_{10} (*P* value) of the most strongly associated classical allele for each gene. The most strongly associated signals are circled. The colored arrows indicate positions that have been conditioned on. The most strongly associated position was HLA-DQβ1 position 57 ($P = 1 \times 10^{-1,355}$). Conditioning on this site, HLA-DRβ1 position 13 was the next independently associated position ($P = 1 \times 10^{-721}$), followed by HLA-DRβ1 position 71 ($P = 1 \times 10^{-95}$). Each position was much more strongly associated than the best classical allele (HLA-DQB1*03:02, HLA-DQA1*02:01 and HLA-DRB1*04:01, respectively).




Figure 3. Effect sizes for amino acid residues. Case (colored bars) and control (unfilled bars) frequencies, as well as unadjusted univariate OR estimates, are shown for each residue at HLA-DQB1 position 57, HLA-DRβ1 position 13 and HLA-DRβ1 position 71.




Figure 4. HLA-DQβ1 position 57, HLA-DRβ1 position 13 and HLA-DRβ1 position 71 are each located in the respective molecule's peptide-binding groove. HLA-DRβ1 positions 13 and 71 line the P4 pocket of the HLA-DR molecule.




Figure 5.

HLA-DQβ1 position 57, HLA-DRβ1 position 13 and HLA-DRβ1 position 71 explain over 90% of the phenotypic variance from the *HLA-DRB1-HLA-DQA1-HLA-DQB1* locus. Assuming the liability threshold model and a global T1D prevalence of 0.4%, all haplotypes in *HLA-DRB1-HLA-DQA1-HLA-DQB1* together explain 29.6% of total phenotypic variance. HLA-DQβ1 position 57 alone explains 15.2% of the variance; the addition of HLA-DRβ1 position 13 and HLA-DRβ1 position 71 increases the explained proportion to 26.9%. Therefore, these three amino acid positions together capture over 90% of the signal within *HLA-DRB1-HLA-DQA1-HLA-DQB1*. In contrast, variation in *HLA-A*, *HLA-B* and *HLA-DPB1* together explain approximately 4% of total variance. Genome-wide independently associated SNPs outside the HLA together explain about 9% of variance; rs678 (in *INS*) and rs2476601 (in *PTPN22*) explain 3.3% and 0.78%, respectively.




Figure 6. Interactions between common *HLA-DRB1–HLA-DQA1–HLA-DQB1* haplotypes lead to observed non-additive effects. We exhaustively tested the seven common haplotypes for pairwise interaction. Of the 21 possible pairs, 11 showed significant interaction effects. Along the perimeter of the diagram, each segment represents one haplotype; red or blue color indicates a risk-conferring or protective additive effect for each haplotype, respectively. Each arc connecting two haplotypes represents a significant interaction. Red indicates additional risk due to the interaction beyond the additive effects, whereas blue indicates reduced risk (protection) due to the interaction beyond the additive effects. The thickness of each arc represents the effect size of the interaction (a thicker red arc means a larger risk effect, whereas a thicker blue arc means a more protective effect). See Table 2 and Supplementary Table 9 for *P* values and effect sizes for all pairwise haplotypic interactions.

Table 1

Haplotypes defined by HLA-DQB1 position 57, HLA-DRβ1 position 13 and HLA-DRβ1 position 71 (control frequency > 0.1%)

Haplotype	OR	Control freq.	Case freq.	Classical HLA-DQB1 alleles	Classical HLA-DRβ1 alleles
A-H-K	2.13	0.050	0.248	0201, 0202, 0302, 0304, 0305	0401, 0409
A-H-E	1.33	0.005	0.016	0201, 0202, 0302, 0304, 0305	0402, 0437
A-S-K (ref)	1.00	0.145	0.332	0201, 0202, 0302, 0304, 0305	0301, 0302, 0304, 1303
A-H-R	0.89	0.054	0.107	0201, 0202, 0302, 0304, 0305	0403, 0404, 0405, 0406, 0407, 0408, 0410, 0411
A-S-E	0.53	0.001	0.001	0201, 0202, 0302, 0304, 0305	1102, 1103, 1301, 1302, 1304
D-F-R	0.48	0.012	0.014	0301, 0303, 0401, 0402, 0503, 0601, 0602, 0603	0101, 0102, 0901, 1001
A-F-R	0.43	0.001	0.001	0201, 0202, 0302, 0304, 0305	0101, 0102, 0901, 1001
S-R-R	0.37	0.008	0.007	0502, 0504	1601, 1602
V-F-R	0.35	0.106	0.085	0501, 0604, 0609	0101, 0102, 0901, 1001
V-S-E	0.34	0.040	0.030	0501, 0604, 0609	1102, 1103, 1301, 1302, 1304
D-G-R	0.32	0.039	0.029	0301, 0303, 0401, 0402, 0503, 0601, 0602, 0603	0801-0806, 1201, 1202, 1404, 1415
D-H-K	0.27	0.068	0.042	0301, 0303, 0401, 0402, 0503, 0601, 0602, 0603	0401, 0409
V-F-E	0.24	0.013	0.006	0501, 0604, 0609	0103
A-Y-R	0.18	0.103	0.043	0201, 0202, 0302, 0304, 0305	0701
D-S-E	0.11	0.058	0.015	0301, 0303, 0401, 0402, 0503, 0601, 0602, 0603	1102, 1103, 1301, 1302, 1304
D-F-E	0.08	0.004	0.001	0301, 0303, 0401, 0402, 0503, 0601, 0602, 0603	0103
D-H-R	0.06	0.017	0.002	0301, 0303, 0401, 0402, 0503, 0601, 0602, 0603	0403-0408, 0410, 0411
D-S-K	0.06	0.010	0.001	0301, 0303, 0401, 0402, 0503, 0601, 0602, 0603	0301, 0302, 0304, 1303
D-S-R	0.05	0.083	0.010	0301, 0303, 0401, 0402, 0503, 0601, 0602, 0603	1101, 1104, 1106, 1108, 1305, 1401, 1402, 1405, 1406, 1407
D-Y-R	0.03	0.041	0.003	0301, 0303, 0401, 0402, 0503, 0601, 0602, 0603	0701
D-R-A	0.02	0.140	0.005	0301, 0303, 0401, 0402, 0503, 0601, 0602, 0603	1501

The 3 amino acid positions define 21 common haplotypes. We list their multivariate ORs and frequencies in controls and cases, as well as the classical four-digit alleles tagged by each haplotype. See Supplementary Table 5b for multivariate ORs and *P* values for all 31 haplotypes formed by HLA-DQB1 position 57, HLA-DRβ1 position 13 and HLA-DRβ1 position 71. Freq., frequency.

Table 2

Pairwise haplotypic interactions in *HLA-DRB1-HLA-DQAI-HLA-DQB1*

	<i>HLA-DRB1</i>	15:01	07:01	04:04	04:01	04:01	D-H-K	A-S-K	V-F-R
<i>HLA-DQAI</i>	Amino acids	D-R-A	A-Y-R	A-H-R	A-H-K	D-H-K	A-S-K	V-F-R	
<i>HLA-DQB1</i>	Additive OR	0.16	0.19	2.77	5.49	1.40	2.83	1.00 (ref)	
01:01	V-F-R	1.00 (ref)	2.32	0.71	2.16	1.95	1.04		
01:01		(0.004)	(0.04)	(0.19)	(1.2×10^{-4})	(7.7×10^{-4})	(0.77)		
05:01									
03:01	A-S-K	2.83	2.24	2.12 ^a	1.96 ^a	0.32			
05:01		(1.2×10^{-5})	(0.03)	(1.9×10^{-4}) ^β	(1.2×10^{-5}) ^β	(9.2×10^{-11})			
02:01									
04:01	D-H-K	1.40	4.78	0.23	0.48				
03:01		(0.03)	(1.1×10^{-4})	(2.4×10^{-6})	(1.1×10^{-3})				
03:01									
04:01	A-H-K	5.49	5.09	0.33					
03:01		(0.03)	(4.2×10^{-5})	(3.5×10^{-5})					
03:02									
04:04	A-H-R	2.77	2.16						
03:01		(0.03)	(0.08)						
03:02									
07:01	A-Y-R	0.19	0.76						
02:01		(0.74)							
02:02									
15:01	D-R-A	0.16							
01:02									
06:02									

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

The table shows, for each given pair of haplotypes, the fold change in OR (from additive effect only) due to interaction. The amino acids column and row denote the residues at HLA-DQB1 position 57, HLA-DRβ1 position 13 and HLA-DRβ1 position 71 corresponding to each haplotype. For each haplotype pair, the *P* value of the interaction term is shown in parentheses. Cells in bold indicate interactions that are significant after Bonferroni correction ($P < 0.05/21 = 0.0024$). The OR of a given diploid genotype is calculated as additive effect_{haplotype 1} × additive effect_{haplotype 2} × interaction_{haplotype 1, haplotype 2} (Supplementary Table 9).

^gThe known HLA-DR3/HLA-DR4 heterozygote effect.